Further use of protein kinase N beta
View Patent ↗The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.
1. A method of treating adenocarcinoma comprising administering to a subject having adenocarcinoma an effective amount of a composition comprising an siRNA molecule or an antisense oligonucleotide that inhibits the activity of protein kinase N beta by causing degradation of a ribonucleic acid encoding protein kinase N beta, wherein protein kinase N beta is up-regulated in adenocarcinoma cells as compared to non-tumor cells of the same lineage.
2. The method according to claim 1 , wherein said siRNA molecule comprises SEQ ID NO: 13 or SEQ ID NO: 14.
3. The method according to claim 1 , wherein said composition comprises an antisense oligonucleotide.
4. The method according to claim 1 , wherein said composition comprises a siRNA molecule.
5. A method of inhibiting or reducing the metastasis or migration of a tumor cell or a hyperplastic cell comprising administering to a subject a composition comprising an siRNA molecule or an antisense oligonucleotide in an amount effective to inhibit the metastasis or migration of said tumor cell or hyperplastic cell, wherein said siRNA molecule or antisense oligonucleotide molecule inhibits the activity of protein kinase N beta by causing degradation of a ribonucleic acid encoding protein kinase N beta and wherein protein kinase N beta is up-regulated in said tumor cell or hyperplastic cell as compared to non-tumor cells or non-hyperplastic cells of the same lineage.
6. The method according to claim 5 , wherein said composition comprises an antisense oligonucleotide.
7. The method according to claim 5 , wherein said composition comprises an siRNA molecule.
8. The method according to claim 5 , wherein said tumor cell or hyperplastic cell is an endometrial cancer cell; a colorectal carcinoma cell; a glioma cell; an adenocarcinoma cell; an endometrial cell displaying hyperplasia; a breast cancer cell; a thyroid cancer cell; an ovarian cancer cell; or a prostate cancer cell.
9. The method according to claim 8 , wherein said tumor cell is an endometrial cancer cell.
10. The method according to claim 8 , wherein said tumor cell is a colorectal carcinoma cell.
11. The method according to claim 8 , wherein said tumor cell is a glioma cell.
12. The method according to claim 8 , wherein said tumor cell is an adenocarcinoma cell.
13. The method according to claim 8 , wherein said hyperplastic cell is an endometrial cell displaying hyperplasia.
14. The method according to claim 8 , wherein said tumor cell is a breast cancer cell.
15. The method according to claim 8 , wherein said tumor cell is a thyroid cancer cell.
16. The method according to claim 8 , wherein said tumor cell is an ovarian cancer cell.
17. The method according to claim 8 , wherein said tumor cell is a prostate cancer cell.
18. A method of treating cancer comprising administering to a subject having a cancer an effective amount of a composition comprising an siRNA molecule or an antisense oligonucleotide that inhibits the activity of protein kinase N beta by causing degradation of a ribonucleic acid encoding protein kinase N beta, wherein protein kinase N beta is up-regulated in the cells of said cancer as compared to non-cancer cells of the same lineage.
19. The method according to claim 18 , wherein said composition comprises an antisense oligonucleotide.
20. The method according to claim 18 , wherein said composition comprises an siRNA molecule.
21. The method according to claim 18 , wherein said cancer cell is an endometrial cancer cell; a colorectal carcinoma cell; a glioma cell; an adenocarcinoma cell; a breast cancer cell; a thyroid cancer cell; an ovarian cancer cell; or a prostate cancer cell.
22. The method according to claim 21 , wherein said cancer cell is an endometrial cancer cell.
23. The method according to claim 21 , wherein said tumor cell is a colorectal carcinoma cell.
24. The method according to claim 21 , wherein said tumor cell is a glioma cell.
25. The method according to claim 21 , wherein said tumor cell is an adenocarcinoma cell.
26. The method according to claim 21 , wherein said tumor cell is a breast cancer cell.
27. The method according to claim 21 , wherein said tumor cell is a thyroid cancer cell.
28. The method according to claim 21 , wherein said tumor cell is an ovarian cancer cell.
29. The method according to claim 21 , wherein said tumor cell is a prostate cancer cell.
30. The method according to claim 1 , wherein said ribonucleic acid encodes SEQ ID NO: 1.
31. The method according to claim 5 , wherein said ribonucleic acid encodes SEQ ID NO: 1.
32. The method according to claim 18 , wherein said ribonucleic acid encodes SEQ ID NO: 1.